N6-methyladenosine (m6A) RNA modification in human cancer

38Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

N6-methyladenosine (m6A) RNA modification, first discovered in 1974, is the most prevalent, abundant and penetrating messenger RNA (mRNA) modification in eukaryotes. This governs the fate of modified transcripts, regulates RNA metabolism and biological processes, and participates in pathogenesis of numerous human diseases, especially in cancer through the reciprocal regulation of m6A methyltransferases (“writers”) and demethylases (“erasers”) and the binding proteins decoding m6A methylation (“readers”). Accumulating evidence indicates a complicated regulation network of m6A modification involving multiple m6A-associated regulatory proteins whose biological functions have been further analysed. This review aimed to summarize the current knowledge on the potential significance and molecular mechanisms of m6A RNA modification in the initiation and progression of cancer.

Cite

CITATION STYLE

APA

Huo, F. C., Zhu, Z. M., & Pei, D. S. (2020, November 1). N6-methyladenosine (m6A) RNA modification in human cancer. Cell Proliferation. Blackwell Publishing Ltd. https://doi.org/10.1111/cpr.12921

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free